Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
NCT07036328, Not applicable, Recruiting, Willem de Haan
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT07036328 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 55 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Willem de Haan | ClinicalTrials.gov |
| Conditions | Alzheimer Disease, Alzheimer Disease, Early Onset | ClinicalTrials.gov |
| Interventions | repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation | ClinicalTrials.gov |
| First posted | 2025-06-25 | ClinicalTrials.gov |
| Last updated | 2026-05-12 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | CDR - Sum of Boxes | from enrollment to 3 month follow-up | Clinical dementia rating - sum of boxes | ClinicalTrials.gov |
| Secondary | Magnetoencephalography (MEG): Spectral analysis | from baseline to week 24 (post-treatment) | Power spectral density (µV²/Hz) computed for different frequency bands . | ClinicalTrials.gov |
| Secondary | Cerebrospinal fluid (CSF) biomarkers | from baseline to week 24 (post-treatment) | Cerebrospinal fluid (CSF) biomarkers are typically reported in picograms per milliliter (pg/mL). This applies to: Amyloid-beta (Aβ₁-₄₂): pg/mL Total tau (t-tau): pg/mL Phosphorylated tau (p-tau, e.g., p-tau181): pg/mL | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: Trail Making Test | from baseline to week 24 (post-treatment) | Assesses visual attention, processing speed, and task switching. Unit: Seconds (completion time) | ClinicalTrials.gov |
| Secondary | Amsterdam instrumental activities of daily living questionnaire (AmsterdamiADL); | baseline to 3 month follow-up | The Amsterdam Instrumental Activities of Daily Living (A-IADL) Questionnaire is a validated tool that assesses cognitive functioning through everyday tasks, with scores ranging from approximately 20 (severe impairment) to 70 (no impairment). | ClinicalTrials.gov |
| Secondary | Mini mental state examination (MMSE) | baseline to 3-month follow up. | The mini-mental state examination (MMSE) test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Higher is better. | ClinicalTrials.gov |
| Secondary | Neuropsychiatric Inventory Questionnaire (NPI-Q) | baseline to 3 month follow up | The Neuropsychiatric Inventory Questionnaire (NPI-Q) is a brief, informant-based tool that assesses 12 neuropsychiatric symptoms in dementia, with total severity scores ranging from 0 to 36 and distress scores from 0 to 60. | ClinicalTrials.gov |
| Secondary | Quick Inventory of Depressive Symptomatology (QIDS) | baseline to 3-month follow up | The Quick Inventory of Depressive Symptomatology (QIDS) is a clinician-rated tool that measures the severity of depressive symptoms, with total scores ranging from 0 (no depression) to 27 (severe depression). | ClinicalTrials.gov |
| Secondary | Magnetoencephalography (MEG): Corrected Amplitude Envelope Correlation (AEC-c) | From baseline to week 24 (post-treatment) | Correlation of the amplitude envelopes of band-pass filtered signals, corrected for signal leakage. | ClinicalTrials.gov |
| Secondary | Magnetoencephalography (MEG): Phase Lag Index (PLI) | baseline to week 24 (post-treatment) | A measure of phase synchronization that is robust to volume conduction. | ClinicalTrials.gov |
| Secondary | Magnetoencephalography (MEG): Joint Permutation Entropy (JPE) | baseline to week 24 (post-treatment) | A nonlinear measure of signal complexity and diversity in joint time series. | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: Verbal Fluency Test | baseline to week 24 (post-treatment) | Measures verbal production and executive functioning. Phonemic fluency (letters D, A, T) Unit: Number of words per 1 minute Semantic fluency (animals) Unit: Number of words per 1 minute | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: Visual Association Test (VAT) | baseline to week 24 (post-treatment) | Detects signs of anterograde amnesia through object-pair associations. Unit: Number of correct associations (maximum score: 12) | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: Stroop Color and Word Test | baseline to week 24 (post-treament) | Evaluates cognitive flexibility, inhibition, and processing speed. Unit: Seconds (per condition), Errors (count) | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: WAIS-III Digit Span (Forward and Backward) | baseline to week 24 (post-treatment) | Assesses attention and verbal working memory. Unit: Span length (maximum correctly repeated digit sequences) | ClinicalTrials.gov |
| Secondary | Neuropsychological evaluation: Rey Auditory Verbal Learning Test (RAVLT) | baseling to week 24 (post-treatment) | Evaluates verbal learning and declarative memory. Immediate recall (Trials I-V) Unit: Total number of words recalled Delayed recall Unit: Number of words recalled Recognition Unit: Number of correct recognitions | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36281767 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)